Tolerability outcomes of NVC 422 administered as a bladder and catheter lavage solution in volunteers

Trial Profile

Tolerability outcomes of NVC 422 administered as a bladder and catheter lavage solution in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2011

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Bacterial infections; Catheter infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors NovaBay Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2011 Planned number of patients changed to 32, according to a media release from NovaBay Pharmaceuticals.
    • 14 May 2008 Status changed from in progress to completed, according to a NovaBay media release.
    • 13 May 2008 Results have been presented in a media release by NovaBay Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top